Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Augusta University
With
National Heart, Lung, and Blood Institute (NHLBI)
The proposed study is designed to investigate the influence of adiposity on ETB receptor function and subsequent vascular responses. The combination of ET-1, ET-3, and the respective ETA and ETB receptor antagonists will be used to provide insight into the mechanisms of ETB receptor dysfunction in the presence of adiposity. Previous studies have revealed elevations in circulating ET-1 in obese individuals; therefore, we predict that obese subjects will exhibit 1) ETB receptor dysfuncton compared to lean subjects and 2) an improvement in ETB receptor dysfunction following treatment with Candesartan.
Age
18–40
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
If you are an adult between the ages of 18-40 year old
You may not be if
Evidence of cardiovascular, pulmonary, renal, hepatic, cerebral, or metabolic disease
Evidence of pregnancy
Using medications that affect vascular tone (i.e., nitrates, etc.)
Use of any anticoagulants (i.e. aspirin)
Anemia
If you are postmenopausal
If you have uncontrolled hypertension (treated resting SBP \>140 mm Hg or DBP \>90 mm Hg)